Antiaging compounds: (-)deprenyl (selegeline) and (-)1-(benzofuran-2-yl)-2-propylaminopentane, [(-)BPAP], a selective highly potent enhancer of the impulse propagation mediated release of catecholamine and serotonin in the brain.

  title={Antiaging compounds: (-)deprenyl (selegeline) and (-)1-(benzofuran-2-yl)-2-propylaminopentane, [(-)BPAP], a selective highly potent enhancer of the impulse propagation mediated release of catecholamine and serotonin in the brain.},
  author={Joseph Knoll},
  journal={CNS drug reviews},
  volume={7 3},
  • J. Knoll
  • Published 7 June 2006
  • Medicine
  • CNS drug reviews
Hundreds of millions of people now die over the age of 80 years primarily due to twentieth century progress in hygiene, chemotherapy, and immunology. With a longer average lifespan, the need to improve quality of life during the latter decades is more compelling. "Aging--The Epidemic of the New Millenium," a recent international conference (Monte Carlo, June 17-18, 2000), showed with peculiar clarity that a safe and efficient drug strategy to slow the age-related decay of brain performance is… 

The significance of selegiline/(−)-deprenyl after 50 years in research and therapy (1965–2015)

The demonstration that the DEP analog (−)-1-phenyl-2-propylaminopentane devoid ofMAO inhibitory property, enhanced like DEP the activity of the catecholaminergic brain engine revealed that this effect is unrelated to the selective inhibition of MAO-B.

The use of the synthetic enhancer substances (-)-deprenyl and (-)-BPAP in major depression.

  • P. GasznerI. Miklya
  • Biology, Chemistry
    Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology
  • 2004
The evaluation of the special pharmacological profile of the synthetic mesencephalic enhancer substance, especially the high potency and the unusual safety and tolerability of (-)-BPAP provide hope that this compound may in the future significantly improve the effectiveness of drug therapy in major depression and its combination with uptake inhibitors may substantially diminish the number of therapy resistant cases.

Acute and delayed effect of (−) deprenyl and (−) 1‐phenyl‐2‐propylaminopentane (PPAP) on the serotonin content of peritoneal cells (white blood cells and mast cells)

The experiments emphasize the necessity of studying the prolonged effects of biologically active molecules, even if they are without acute effects, as serotonin is a modulator of the immune system and the influence on immune cells of the molecules studied can contribute to their enhancing effect.



Pharmacological basis of the therapeutic effect of (−)deprenyl in age‐related neurological diseases

  • J. Knoll
  • Biology
    Medicinal research reviews
  • 1992
It is concluded that in Parkinson's disease and Alzheimer's disease patients need to be treated daily with 10 mg (-)deprenyl from diagnosis until death, irrespective of other medication.

The effect of deprenyl (selegiline) on the natural history of Parkinson's disease.

Early deprenyl therapy delays the requirement for antiparkinsonian medication, possibly by slowing progression of the disease.

(-)Deprenyl (selegiline), a catecholaminergic activity enhancer (CAE) substance acting in the brain.

  • J. Knoll
  • Biology, Psychology
    Pharmacology & toxicology
  • 1998
It may be supposed that a prophylactic low dose administration of a safe catecholaminergic activity enhancer substance during the postdevelopmental phase of life will slow the age-related decline of behavioral performances, delay natural death and decrease susceptibility to Parkinson's disease and Alzheimer's disease.

Deprenyl (selegiline): the history of its development and pharmacological action

  • J. Knoll
  • Biology, Chemistry
    Acta neurologica Scandinavica. Supplementum
  • 1983
Deprenyl inhibits MAO‐B selectively in different animal species and in man and is able to block MAO-B activity in the brain selectively in vivo in four species with s.c. administration.

Preclinical Evaluation of l-Deprenyl: Lack of Amphetamine-Like Abuse Potential

Evaluation of l-deprenyl for cocaine-like abuse liability is a relevant topic of research because the reinforcing effects of cocaine may be mediated by inhibition of dopamine reuptake, and l-Deprenyl, in addition to its MAO-B actions, also inhibits dopamine reptake.